30May

ASCO: Results of KEYNOTE-355

Abstract No : 1000

Abstract Type : Oral Abstract Session

Indication : Triple Negative Breast Cancer

Intervention : pembrolizumab + chemotherapy

Company : Merck

Technology : Monoclonal Antibody


Results:

At data cutoff, 153 pts were randomized to pembro and 154 to chemo. Median (range) study follow-up was 28.4 mo (0.2-48.3) with pembro vs 27.2 mo (0.8-46.6) with chemo. Pembro was superior to chemo for PFS (median 16.5 mo vs 8.2 mo; HR 0.60; 95% CI, 0.45-0.80; P=0.0002). The 12- and 24-mo PFS rates were 55.3% and 48.3% with pembro vs 37.3% and 18.6% with chemo. Confirmed ORR was 43.8% vs 33.1%; median (range) duration of response was not reached (2.3+ to 41.4+) with pembro vs 10.6 mo (2.8 to 37.5+) with chemo. Grade 3-5 treatment related adverse event (AE) rates were 22% vs 66% for pembro vs chemo. One pt in the chemo arm died due to a treatment-related AE.


Conclusion:

Pembro combined with several chemo partners showed a statistically significant and clinically meaningful improvement in PFS vs chemo alone in pts with previously untreated locally recurrent inoperable or metastatic TNBC whose tumors expressed PD-L1 (CPS >=10). Pembro + chemo was generally well tolerated, with no new safety concerns.


Commentary:

Enough evidence to support the addition of pembrolizumab to standard chemotherapy for the first line treatment of mTNBC as per KEYNOTE-355 trial.


Refer to Triple Negative Breast Cancer Market report for detailed Insights.